Item 7.01 Regulation FD Disclosure.
On November 17, 2022, the Company updated the slide deck presentation posted on its website to include additional information related to veverimer. While this presentation does not change and is not intended to change the previously disclosed negative results of the VALOR-CKD trial, the information is being provided in conjunction with the Company's exploration of strategic alternatives and to maximize the information publicly available on veverimer to any third parties with potential interest in the Company and/or veverimer. While the Company is devoting significant efforts to identify and evaluate potential strategic alternatives, there can be no assurance that this strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated, or lead to any stockholder value.
A form of the Company’s slide presentation is being furnished as Exhibit 99.1 to
this Current Report on Form 8-K, and a copy is available on the Company’s
website at IR.Tricida.com.
The information included under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit Number Description 99.1 Company Presentation . 104 Cover Page Interactive Data File (embedded
within the Inline XBRL document).
© Edgar Online, source Glimpses